Key Numbers
- Q1 revenue: $209.5 million, up 5% year over year
- Net income: $1.5 million vs. $34.7 million loss last year
- Adjusted EBITDA: $10 million, up 9%
- Operating cash flow: -$1.3 million vs. -$35.3 million last year
- Cannabis revenue (two-year comparison): down 8%
Tilray Brands (NASDAQ: TLRY) has seen its stock price skyrocket from under $0.40 in June to over $2 in early October, fueled by growing investor optimism and a rare earnings-driven rally. Shares surged 22% after the company released Q1 fiscal 2026 results, defying its usual post-earnings slide. While the jump suggests bullish sentiment, a deeper dive into the numbers reveals more modest improvements than the market reaction might suggest.
Revenue rose 5% year over year to $209.5 million, driven largely by stabilization in its alcohol and pharmaceutical distribution segments. Cannabis sales appeared strong at first glance, but are benefiting from weak comparables. Tilray’s cannabis revenue declined 13% last year and remains down 8% on a two-year basis, indicating the growth may be less organic and more a rebound from prior softness.
The headline profit of $1.5 million marks a dramatic shift from last year’s $34.7 million loss. However, two non-cash items heavily influenced this result: a $17.9 million drop in amortization expenses and a $15 million gain from the revaluation of contingent consideration related to the Montauk Brewing acquisition. This gain is not likely to recur and suggests that the company’s earnings quality is low. When adjusting for these, Tilray’s profitability picture becomes much less impressive.
Meanwhile, cash flow remains negative, with operating cash flow at -$1.3 million for the quarter. While that’s an improvement from the -$35.3 million reported last year, it still signals the company is not yet generating positive cash from its core operations. Without access to the U.S. cannabis market—still off-limits due to federal prohibition—Tilray’s long-term growth potential remains uncertain. Its strategy of acquiring smaller alcohol brands provides some diversification, but doesn’t fundamentally change the business’s risk profile.
Given the continued cash burn, reliance on non-repeatable earnings drivers, and limited growth avenues, Tilray may appeal only to high-risk investors betting on future U.S. cannabis legalization. For most others, especially value or income-focused investors, the fundamentals remain too shaky to justify chasing the recent hype.